Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||GSK3203591 + GSK3368715|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|GSK3203591||GSK591|EPZ015866||GSK3203591 inhibits PRMT5, potentially resulting in decreased tumor cell growth (PMID: 29946150).|
|GSK3368715||EPZ019997|GSK-3368715|GSK 3368715||GSK3368715 (EPZ019997) inhibits members of the type I PRMT family, which potentially in decreased tumor growth (PMID: 31257072).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||pancreatic adenocarcinoma||not applicable||GSK3203591 + GSK3368715||Preclinical - Cell line xenograft||Actionable||In a preclinical study, the combination of GSK3203591 and GSK3368715 inhibited tumor growth in a pancreatic adenocarcinoma cell line xenograft model, demonstrating increased efficacy over either agent alone (PMID: 31257072).||31257072|
|Unknown unknown||diffuse large B-cell lymphoma||not applicable||GSK3203591 + GSK3368715||Preclinical - Cell culture||Actionable||In a preclinical study, GSK3203591 and GSK3368715 worked synergistically to inhibit viability of diffuse large B-cell lymphoma cell lines in culture (PMID: 31257072).||31257072|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|